Except as provided elsewhere in this policy, no investigator may involve a
human being as a subject in research covered by this policy unless the
investigator has obtained the legally effective informed consent of the subject
or the subject’s legally authorized representative. An investigator shall seek
such consent only under circumstances that provide the prospective subject or
the representative sufficient opportunity to consider whether or not to
participate and that minimize the possibility of coercion or undue influence.
The information that is given to the subject or the representative shall be in
language understandable to the subject or the representative. No informed
consent, whether oral or written, may include any exculpatory language
through which the subject or the representative is made to waive or appear to
waive any of the subject’s legal rights, or releases or appears to release the
investigator, the sponsor, the institution, or its agents from liability for
negligence.
(a) Basic elements of informed consent. Except as provided in paragraph (c) or
(d) of this section, in seeking informed consent the following information shall
be provided to each subject:
(1) A statement that the study involves research, an explanation of the
purposes of the research and the expected duration of the subject’s
participation, a description of the procedures to be followed, and identification
of any procedures which are experimental;
(2) A description of any reasonably foreseeable risks or discomforts to the
subject;
(3) A description of any benefits to the subject or to others which may
reasonably be expected from the research;
(4) A disclosure of appropriate alternative procedures or courses of treatment,
if any, that might be advantageous to the subject;
(5) A statement describing the extent, if any, to which confidentiality of records
identifying the subject will be maintained;
(6) For research involving more than minimal risk, an explanation as to whether
any compensation and an explanation as to whether any medical treatments
are available if injury occurs and, if so, what they consist of, or where further
information may be obtained;
(7) An explanation of whom to contact for answers to pertinent questions about
the research and research subjects’ rights, and whom to contact in the event of
a research-related injury to the subject; and
(8) A statement that participation is voluntary, refusal to participate will involve
no penalty or loss of benefits to which the subject is otherwise entitled, and
the subject may discontinue participation at any time without penalty or loss of
benefits to which the subject is otherwise entitled.
(b) Additional elements of informed consent. When appropriate, one or more of
the following elements of information shall also be provided to each subject:
(1) A statement that the particular treatment or procedure may involve risks to
the subject (or to the embryo or fetus, if the subject is or may become
pregnant) which are currently unforeseeable;
(2) Anticipated circumstances under which the subject’s participation may be
terminated by the investigator without regard to the subject’s consent;
(3) Any additional costs to the subject that may result from participation in the
research;
(4) The consequences of a subject’s decision to withdraw from the research and
procedures for orderly termination of participation by the subject;
(5) A statement that significant new findings developed during the course of
the research which may relate to the subject’s willingness to continue
participation will be provided to the subject; and
(6) The approximate number of subjects involved in the study.
(c) An IRB may approve a consent procedure which does not include, or which
alters, some or all of the elements of informed consent set forth above, or
waive the requirement to obtain informed consent provided the IRB finds and
documents that:
(1) The research or demonstration project is to be conducted by or subject to
the approval of state or local government officials and is designed to study,
evaluate, or otherwise examine: (i) Public benefit of service programs; (ii)
procedures for obtaining benefits or services under those programs; (iii)
possible changes in or alternatives to those programs or procedures; or (iv)
possible changes in methods or levels of payment for benefits or services
under those programs; and
(2) The research could not practicably be carried out without the waiver or
alteration.
(d) An IRB may approve a consent procedure which does not include, or which
alters, some or all of the elements of informed consent set forth in this section,
or waive the requirements to obtain informed consent provided the IRB finds
and documents that:
(1) The research involves no more than minimal risk to the subjects;
(2) The waiver or alteration will not adversely affect the rights and welfare of
the subjects;
(3) The research could not practicably be carried out without the waiver or
alteration; and
(4) Whenever appropriate, the subjects will be provided with additional
pertinent information after participation.
(e) The informed consent requirements in this policy are not intended to
preempt any applicable federal, state, or local laws which require additional
information to be disclosed in order for informed consent to be legally effective.
(f) Nothing in this policy is intended to limit the authority of a physician to
provide emergency medical care, to the extent the physician is permitted to do
so under applicable federal, state, or local law.